FindTrial
Sign In

The prediction of tumor progression by changes in peripheral blood immune cell populations before and after radiotherapy and chemotherapy in patients with solid tumors

The prediction of tumor progression by changes in peripheral blood immune cell populations before and after radiotherapy and chemotherapy in patients with solid tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107327
Enrollment
Unknown
Registered
2025-08-08
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor

Interventions

Observation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: This study plans to enroll 200 patients with solid malignant tumors, including but not limited to lung cancer and esophageal cancer, admitted to the outpatient and ward departments of the Oncology Department at West China Hospital, Sichuan University. 1. Pathological diagnosis of solid malignant tumor, stage I-IV 2. Basic condition is stable, cognitive ability is intact, and they are able to undergo chemotherapy and radiotherapy. 3. Age >=18 years

Exclusion criteria

Exclusion criteria: 1. The patient's condition has progressed and they are unable to continue cancer treatment. 2. The patient has a severe systemic infection and requires antibiotic treatment.

Design outcomes

Primary

MeasureTime frame
Changes in peripheral blood immune cell populations;—

Secondary

MeasureTime frame
Changes in peripheral blood immune cell CD61 expression;—

Countries

China

Contacts

Public ContactWang Manni

West China Hospital of Sichuan University

932345093@qq.com+86 189 8060 8267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026